ABSTRACT
Objective: To evaluate the clinical efficacy and safety of Levornidazole and sodium chloride injection in treating patients with bacterial liver abscess. Methods: 94 patients with bacterial liver abscess who need anti-anaerobion treatment were enrolled in this study. And all of them were divided into observation group (47 cases) and control group (47 cases). The patients of observation group received intravenous drip infusion of Levornidazole and sodium chloride injection, while patients of control group received intravenous drip infusion of Omidazole injection. The dosage of two groups was 0.5g, 2 times/d, 5-10d per a course. The clinical efficiency, bacteriology efficiency and the occurrence rate of adverse reaction between two groups were compared and researched. Results: The differences of clinically effective rate and clearance rate of bacteria between observation group (95.74% and 93.33%) and control group (89.36% and 88.23%) were not significant (x2=0.62, x2=1.30, P>0.05). The difference of average hospital stay time between observation group (13.47 d) and control group (14.86 d) also was no significant (t=0.96, P>0.05). After the drug therapy, the occurrence rates of adverse reactions, included of gastrointestinal reaction, anaphylaxis and abnormal liver function, of observation group was no significantly lower than that of control group (x2=0.26, x2=0.51, x2=0.51, P>0.05). While the adverse reaction rate of central nervous system of observation group (0) was significant lower than that of control group(14.89%) (x2=5.56, P<0.05). Conclusion: Levornidazole treating the bacterial liver abscess can obtain significant efficacy and safety, and it has higher clinical application value.